Thrombosis and Hemostasis Biomarkers Market Report 2026

The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $5.17 billion in 2025 to $5.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of coagulation biomarkers, reliance on manual and semi-automated analyzers, increasing prevalence of cardiovascular disorders, growing diagnostic laboratory infrastructure, rising awareness of thrombosis and hemostasis disorders.

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to technological advancements in fully automated analyzers, increasing adoption of poct coagulation devices, rising investment in personalized medicine, expansion of pharmaceutical and diagnostic research, development of novel biomarkers for early disease detection. Major trends in the forecast period include growing adoption of advanced coagulation analyzers, rising demand for point-of-care testing solutions, increased focus on early detection of cardiovascular disorders, expansion of diagnostic reagents and immunoassay kits, integration of biomarker testing in personalized medicine.

The growing demand for precise and targeted therapies is expected to propel the growth of the thrombosis and hemostasis biomarkers market going forward. Precise and targeted therapies involve advanced treatment approaches that focus on the specific molecular and genetic features of a patient’s disease, with the goal of improving treatment effectiveness while reducing unwanted side effects. The demand for such therapies is increasing due to expanding knowledge of genetic and molecular disease variations, which enables more personalized treatment strategies that enhance clinical outcomes and minimize adverse reactions. This demand supports the thrombosis and hemostasis biomarkers market by driving the development of highly accurate diagnostic tools capable of identifying specific biomarkers, allowing for better-targeted therapies for clotting disorders and improved patient outcomes. For instance, in March 2024, according to Novotech, an Australia-based contract research organization (CRO), among the 217 oncology therapies approved by the U.S. Food and Drug Administration by the end of 2023, 43% were categorized as precision oncology treatments, with 78 incorporating biomarkers detectable through deoxyribonucleic acid (DNA) or next-generation sequencing (NGS). Therefore, the growing demand for precise and targeted therapies is driving the growth of the thrombosis and hemostasis biomarkers market.

Major companies operating in the thrombosis and hemostasis biomarkers market are concentrating on developing advanced solutions such as automation integration to streamline laboratory workflows and enhance testing accuracy. Automation integration in clinical laboratories refers to the implementation of connected automated systems, instruments, and robotic technologies that carry out laboratory testing processes with minimal manual involvement. For example, in April 2024, Siemens Healthcare, a Germany-based medical technology company, in collaboration with Sysmex Corporation, a Japan-based medical technology company, launched a combined portfolio of hemostasis testing solutions for laboratories. This portfolio includes a broad range of established instruments and assay kits designed to support diagnostic testing for bleeding and clotting disorders, enabling dynamic sample routing with automated reflex testing. These capabilities help reduce turnaround times and increase testing throughput without requiring additional staff. Furthermore, automation supports centralized control and real-time monitoring, facilitating intelligent workflow management, integrated quality control, and optimized resource utilization.

In February 2024, Procuritas Capital Investors, a Sweden-based private equity firm, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This acquisition aims to strengthen Procuritas’ presence in the rapidly growing thrombosis and hemostasis diagnostics market by leveraging Precision BioLogic’s FDA-cleared reagents, plasma-based products, and strong research and development capabilities, along with Affinity Biologicals’ custom assay services, to capitalize on global healthcare trends. Precision BioLogic (PBI) is a Canada-based provider of diagnostic products for blood coagulation disorders, while Affinity Biologicals is a Canada-based manufacturer of products used in thrombosis and hemostasis research and diagnostics.

Major companies operating in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company (BD), Mayo Clinic Laboratories, bioMérieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH.

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thrombosis and hemostasis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombosis and hemostasis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the thrombosis and hemostasis biomarkers market by increasing the cost of imported analyzers, reagents, and calibration materials. Segments such as fully automated coagulation analyzers and specialized immunoassay kits are most impacted, particularly in regions like Asia-Pacific and Europe where imports constitute a significant portion of supply. The tariffs have led to higher production costs and slowed expansion in some regions. Positively, tariffs are driving local manufacturing, innovation in reagent formulations, and investment in domestic diagnostic capabilities.

The thrombosis and hemostasis biomarkers market research report is one of a series of new reports that provides thrombosis and hemostasis biomarkers market statistics, including thrombosis and hemostasis biomarkers industry global market size, regional shares, competitors with a thrombosis and hemostasis biomarkers market share, detailed thrombosis and hemostasis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the thrombosis and hemostasis biomarkers industry. This thrombosis and hemostasis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thrombosis and hemostasis biomarkers are biological indicators that offer insights into blood clot formation and the mechanisms that regulate bleeding. These biomarkers assist in assessing the balance between coagulation and clot breakdown, making them essential for evaluating vascular health and diagnosing coagulation-related disorders.

The main products associated with thrombosis and hemostasis biomarkers include reagents and consumables, as well as analyzers. Reagents and consumables consist of critical chemical substances and disposable laboratory materials such as assay kits, buffers, calibrators, and control solutions that are used to detect, measure, and analyze biomarkers related to clotting and bleeding conditions. These biomarkers are assessed using various tests, including D-dimer, antithrombin III, plasminogen, soluble fibrin, factor VIII, prothrombin time (PT), activated partial thromboplastin time (APTT), and others. They are applied across multiple clinical areas such as cardiovascular diseases, neurological disorders, oncology, pregnancy-related conditions, and orthopedic procedures, and are utilized by end users including hospitals, diagnostic laboratories, pharmaceutical companies, academic institutions, and home healthcare settings.

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.